Inrebic (fedratinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			
MALE FEMALE HEIGHT (IN/CM): WEIGH	IT (LB/KG): ALLERGIES:		

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):				

Continued on next page.



Inrebic (fedratinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	MEDICATIONS FOR THIS CONDITION? DURATION OF THERAPY (SPECIFY DATES):	YES (if yes, complete below) NO RESPONSE/REASON FOR FAILURE/ALLERGY:		
Direct NAME AND DOSAGEJ.				
2. LIST DIAGNOSES:		ICD-10:		
Myelofibrosis				
Other diagnosis:ICD-	10			
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Does the patient have a diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia)? Yes No Please submit documentation 				
Does the patient have constitutional symptoms? Yes No Please submit documentation				
Does have a hemoglobin level less than 10 g/dL? So Yes No Please submit documentation				
Does the patient have a WBC count gr	eater than 25 x 10°/L? 🗆 Yes 🗆 No 🛛 F	lease submit documentation		
Does the patient have blood blasts on a peripheral smear equaling 1% or greater?				
Does the patient have an enlarged spleen at least 5cm below the costal margin?				
Has the patient undergone a bone marrow biopsy including semiquantitative evaluation of fibrosis, which showed megakaryocytic proliferation and atypia accompanied by either reticulin and/or collagen fibrosis grades 2 or 3? • Yes • No Please submit documentation				
Does the patient have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (is ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours)?				
Does the patient have an absolute neutrophil count (ANC) equaling at least 1.0 x 10 ⁹ /L?				
Does the patient have a platelet count of at least 50 x 10^9 / L? \Box Yes \Box No Please submit documentation				
Has the patient received prior treatment with a JAK2 inhibitor (such as ruxolitinib/ Jakafi® or fedratinib/ Inrebic®)?				



Inrebic (fedratinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

Are there any other comments, diagnoses, symptoms, medications to physician feels is important to this review?	ried or failed, and/or any other information the
*Please note: Not all drugs/diagnoses are covered on all plans. This re information is received.	quest may be denied unless all required
ATTESTATION: I attest the information provided is true and accurate the Health Plan, insurer, Medical Group or its designees may perform information necessary to verify the accuracy of the information report	a routine audit and request the medical
Prescriber Signature or Electronic I.D. Verification:	Date:
CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain convolution you are not the intended recipient, you are hereby notified that any disclosure, copying of these documents is strictly prohibited. If you have received this information in error and arrange for the return or destruction of these documents.	ng, distribution, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

